“Preclinical research and clinical trials of a first-in-class drug candidate in therapy of invasive systemic mycoses,” was granted a subsidy from the Operational Programme: Smart Development, Step 1.1, sub-measure 1.1.1 “Industrial research and development operations executed by companies.” Its implementation is sheduled for the period between January 2016 and December 2018.
Project called ”BioFuture – innovative services and products in the scope of biotechnology in the Pomerania [northern Poland] region” received funding under Action 1.2. of Regional Operational Program for Pomerania Province for the years 2007-2013.
The project supports development of an innovative profile of BLIRT by aquirement of ultramodern biotechnological equipment followed by a specific training programme for its use.
Project called ”Increasing competitiveness of BLIRT Ltd. through the development of export – Phase I” received funding under the Action 6.1 of Operational Program Innovative Economy.
The project is associated with the establishment of an Export Development Plan for BLIRT to EU, USA and Japanese markets.
Project called ”Metagenomics as a source of production of new biocatalysts” received funding under the Action 1.4 – 4.1 of Operational Program Innovative Economy.
The main scope of the project is focused on the application of metagenomics for the development of innovative biocatalysts for the industrial biotechnology.
Within the scope of the Applied Research Program co-financed by the National Center for Research and Development in a consortium comprising of Gdansk Medical University – Consortium Leader, Silesian University of Technology, Oncology Center in Gliwice and BLIRT S.A. – as a Consortium Partner, the company implements the project “MOLTEST BIS – Validation of Molecular Early Lung Cancer Identification Signs in High Risk Group.” The project budget is 6,702,935 PLN and involves the clinical trial of 7,000 people at high risk of lung cancer with the use of CT scan and blood sampling to validate innovative screening tests for early lung cancer. BLIRT’s task is to develop a prototype of ELISA type diagnostics and technology of semi-products production.